key: cord-1053234-34n66cv2
authors: Zanelli, S.; Fiorio, E.; Zampiva, I.; Zacchi, F.; Borghesani, G.; Giontella, E.; Parolin, V.; Biondani, P.; Zuliani, S.; Dieci, M.V.; Mioranza, E.; Zorzi, M.; Conti, M.; Gibellini, D.; Verlato, G.; Milella, M.
title: Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.
date: 2022-03-09
journal: Ann Oncol
DOI: 10.1016/j.annonc.2022.02.227
sha: 1470883f88734c01d26bd07a646639d008af7c24
doc_id: 1053234
cord_uid: 34n66cv2

nan

Cancer patients/survivors are at high risk of SARS-CoV-2 infection and 2-to 3-fold more likely to develop severe complications and death 1 , with female gender being relatively protected 2 . Little evidence is currently available about specific associations between coronavirus disease-19 (COVID-19) and breast cancer (BC).

As part of a cohort of 979 oncological patients tested for SARS-CoV-2 by RT-PCR according to the strategy implemented by the Veneto Oncology Network (ROV) 3 Table S1 ).

Anti-cancer treatment distribution at the time of testing significantly differed between the two groups ( Figure 1A) . The risk of infection was the lowest among BC patients undergoing chemotherapy (CHT), either alone (9%) or combined with hormonal treatment (HT) (15%), intermediate among those receiving HT only (24%), while nearly all patients not receiving active treatment (8/9) tested positive (p <0.001). None of the BC patients with SARS-CoV-2 infection developed severe COVID-19, six patients required hospitalization (2 of which belonged to the CHT group) and none died from disease; patients undergoing CHT were more likely to develop symptomatic disease (p=0.025) ( Figure 1B) .

Epidemiological data gathered in the Veneto region between February and April 2020 4 suggested that BC patients might have a higher risk of hospitalization for COVID-19 and that anti-estrogenic treatment might reduce its prevalence in this patient population. However, in the first wave of the pandemic SARS-CoV-2 testing was almost exclusively driven by symptoms, potentially missing asymptomatic cases. In our study, screening was targeted at asymptomatic subjects: under these conditions, HT did not appear to influence the risk and severity of SARS-CoV-2 infection within J o u r n a l P r e -p r o o f the BC population. However, the prevalence of infection among BC patients undergoing HT is still higher than that of the general population; this leaves open the possibility that menopausal status and HT might influence susceptibility to SARS-CoV-2 infection, even though the mechanistic explanation for such association remains elusive. 5 BC patients undergoing CHT were less likely to be infected, but when they did, they developed a more severe form of COVID-19, while patients not undergoing active treatment were at higher risk of infection. Consistently, recent epidemiological data showed that the risk of SARS-CoV-2 infection is higher in patients diagnosed and treated for cancer more than 12 months before SARS-CoV-2 testing (prevalent-inactive cases), while the risk of death is higher for patients newly diagnosed or undergoing active treatment (incident or prevalent-active cases) 6 . These results may be related to the stricter compliance of BC patients undergoing CHT with social distancing requirements, as well as to the more frequent SARS-CoV-2 screening in patients at high risk of myelosuppression 3 .

Since such evidence might be useful to improve on current surveillance and management strategies, taking into account the circulation and clinical expressivity of different SARS-CoV-2 variants and the impact of the vaccination campaign, we plan to confirm our findings in a larger contemporary cohort from ROV and validate them using epidemiological data. 

Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer

SARS-CoV-2 Infection in Cancer Patients: A Population-Based Study